| 11.30 |
|
Minivorträge ausgewählter Abstracts I
Vorsitz: Martin Wehling, Mannheim
- Michael Böttcher, Wuppertal
The incidence of adverse events in First in Man trials - Andreas Fuchs, Dresden
Drug information service
for physicians - experiences from more than 10 years in
Dresden
- Tilman Heinrich, Heidelberg
Impact of long term (14 days) efavirenz administration on CYP3A4 activity
- Sven Schmiedl, Wuppertal
Comparison of predicted and observed drug serum levels in pediatric patients using
the physiology-based pharmacokinetic (PBBK) model PK-SIM® - a pilot study
|
|
Minivorträge ausgewählter Abstracts II
Vorsitz: Frank Donath, Erfurt
- Karin Kuczka, Frankfurt/Main
Effects of the HIV-1 protease inhibitor tipranavir on platelet aggregation in patients
and in vitro and on in vitro thromboxane B2 formation
- Cornelia Remmler, Kiel
Impact of ABCA1 and MPO variants on plasma lipid levels of CAD patients
- Heike Knüpfer, Leipzig
Results and indications that breast cancer patients could have a benefit from an anti-IL-6 treatment regiment
- Everlyn Sawa, Heidelberg
Metabolism of tilidine by human liver microsomes, CYP3A4, and CYP2C19
|
|
|
VKliPha2007 Programm (pdf file - 991kB)